Category Archives

News

Statement from SCDAA MARAC

  • February 17, 2021
  • admin

February 16, 2021 – We are aware of the announcement today from bluebird bio regarding the temporary suspension of the clinical... Continue Reading

MARAC Advisory Statement: COVID-19 Vaccines

  • December 15, 2020
  • admin

Download the MARAC Alert | Download Spanish Translation | Download French Translation December 14, 2020 – News is evolving rapidly about... Continue Reading

Sickle Cell Disease Association of America and Aruvant Sciences Forge New Partnership to Educate Around Gene Therapy

  • October 13, 2020
  • admin

The Sickle Cell Disease Association of America (SCDAA) and Aruvant Sciences are proud to announce a new partnership to create educational... Continue Reading

Sickle Cell Disease Association holds 48th annual national convention virtually

  • October 5, 2020
  • admin

Sickle Cell Disease Association of America will hold its 48th annual national convention virtually this year from Tuesday, Oct. 13, through... Continue Reading

Sickle Cell Disease Association of America Partners with HealthWell Foundation

  • April 17, 2020
  • admin

New Fund Launches to Provide Financial Assistance to People with Sickle Cell Disease Copayment and Premium Assistance Now Available (April 15,... Continue Reading

NEW – Sickle Cell Disease and COVID-19: Provider Advisory

  • March 18, 2020
  • admin

Download Provider Advisory Download Sub-Saharan African Provider Advisory An Outline to Decrease Burden and Minimize Morbidity This document will be updated... Continue Reading

NEW – Health Alert for People with Sickle Cell Disease and their Caregivers

  • March 17, 2020
  • admin

DOWNLOAD PATIENT PDF     (Spanish Version) DOWNLOAD PATIENT SUB-SAHARAN AFRICAN PDF SHOW THIS TO YOUR MEDICAL PROVIDERS TO HELP THEM HELP... Continue Reading

ASH and FDA Unveil New Recommendations to Guide Clinical Development of Sickle Cell Disease Therapies

  • December 13, 2019
  • admin

Joint FDA/ASH Led Initiative Highlights Importance of Using Patient Reported Outcomes and Biomarkers in Clinical Trials to Advance SCD Therapies (WASHINGTON,... Continue Reading

GBT’s Oxbryta™ (voxelotor) tablets is approved for the treatment of sickle cell disease

  • December 3, 2019
  • admin

Oxbryta™ (voxelotor) tablets Now Approved On behalf of GBT, we are happy to share that Oxbryta (pronounced ox-brye-ta) is now approved... Continue Reading

CRISPR Therapeutics and Vertex Announce Positive Safety and Efficacy Data

  • November 19, 2019
  • admin

Nov 19, 2019 CRISPR Therapeutics and Vertex Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9... Continue Reading